Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$TGTX Q3 '25 Earnings Results & Recap TG Therapeutics reported Q3 revenue of $161.7M, beating estimates of $152.11M, and EPS of $2.43, which includes a one-time, non-recurring $365 million tax benefit; adjusted EPS is closer to $0.20, with full year revenue guidance raised to $585M.
1
1
1

Since Post

Full Details
SteveTexans
It is smart! Bearish comment is false comment. MBA programs and I came from Fortune 100 company, C Suite always focuses on ROI and ROE. Rightly so..Too many compounds are failures. Currently, with their debt and two outstanding compounds, develops these and stay the course.
6